Diabetes

Late-life diabetes status tied to new cognitive impairment

(HealthDay)—Having diabetes, poor glycemic control, and longer diabetes duration are associated with worse cognitive outcomes in older adults during a median follow-up of five years, according to a study recently published ...

Diabetes

Study links irregular sleep patterns to metabolic disorders

A new study has found that not sticking to a regular bedtime and wakeup schedule—and getting different amounts of sleep each night—can put a person at higher risk for obesity, high cholesterol, hypertension, high blood ...

Health

Extending sleep may lower cardiometabolic risk

Increasing sleep duration may help reduce cardiometabolic risk—or the risk of heart disease and metabolic disorders— in individuals who do not get enough sleep, according to an analysis of all published studies on the ...

Diseases, Conditions, Syndromes

Zerbaxa approved for hospital-acquired bacterial pneumonia

(HealthDay)—Zerbaxa (ceftolozane and tazobactam) has been approved for a new indication to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients aged 18 years ...

Health

Why lack of sleep is bad for your heart

In recent years, numerous studies have shown that people who don't get enough sleep are at greater risk of stroke and heart attack.

Diabetes

Sleep duration tied to adverse measures of glycemia

(HealthDay)—Self-reported short and long sleep are both associated with adverse measures of glycemia among adults with prediabetes, according to a study published online May 10 in Diabetes Care.

Health

The surprising benefits of weekend workouts

(HealthDay)—You know the value of exercise for maintaining good health and managing chronic conditions like arthritis, but you also know how hard it is to fit daily workouts into a busy schedule to meet weekly minimums.

Diseases, Conditions, Syndromes

FDA approves mavyret for children, adolescents with hep C

(HealthDay)—Mavyret (glecaprevir and pibrentasvir) tablets are now approved to treat all six genotypes of hepatitis C virus (HCV) in children ages 12 to 17 years, the U.S. Food and Drug Administration announced yesterday.

page 1 from 23

Duration

Duration may refer to:

This text uses material from Wikipedia, licensed under CC BY-SA